News

Patients with Lambert-Eaton myasthenic syndrome (LEMS) and cerebellar ataxia may have autoantibodies against calcium channels, a Mayo Clinic study indicates. The study, titled “Calcium Channel Autoimmunity: Cerebellar Ataxia and Lambert-Eaton Syndrome Coexisting,” appeared in the journal Muscle & Nerve. Patients with LEMS typically show muscle…

Lambert-Eaton myasthenic syndrome (LEMS) can occur along with other autoimmune diseases affecting the nervous system, namely limbic encephalitis, in patients with lung cancer, a case study found. The study, “Coexistence of Lambert–Eaton myasthenic syndrome and autoimmune encephalitis with anti-CRMP5/CV2 and anti-GABAB receptor antibodies in small cell lung cancer: A case…

Lambert-Eaton myasthenic syndrome (LEMS) that’s not associated with cancer is associated with early onset of the disease, but it does not have an impact on the long-term survival of patients, according to researchers. These findings are from a large-scale study conducted by Duke Myasthenia Gravis Clinic researchers. The team…

Lambert-Eaton myasthenic syndrome (LEMS) has been linked to cancer, with more than half of LEMS patients having cancer, most of them a small cell lung cancer (SCLC). Researchers have now reported a rare case of LEMS associated with two types of cancer in a patient: breast cancer and small cell…

University of Missouri researchers presented a rare case of Lambert–Eaton myasthenic syndrome (LEMS) that initially showed eye muscle weakness as a primary symptom in a 59-year-old woman, according to a report in the journal Cureus. Myasthenia gravis and LEMS are two autoimmune disorders that share a…

Catalyst Pharmaceuticals filed a New Drug Application (NDA) with the U.S. Food and Drug Administration for Firdapse (amifampridine) as a treatment for Lambert-Eaton myasthenic syndrome (LEMS). “We are pleased to reach this regulatory milestone and believe that our NDA submission contains all of the necessary information…